Adalimumab therapy for childhood uveitis

Adalimumab therapy for childhood uveitis

Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) ( P < .001; 2 tailed paired Wilcoxon rank sum test). No significant ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pediatrics 2006-10, Vol.149 (4), p.572-575
Hauptverfasser: Vazquez-Cobian, Liza B., Flynn, Thomas, Lehman, Thomas J.A.
Format: Artikel
Sprache:eng
Schlagworte:
Adalimumab
Adolescent
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Child
Child, Preschool
Female
General aspects
Humans
Male
Medical sciences
Ophthalmology
Prospective Studies
Tumor Necrosis Factor-alpha
Uvea diseases
Uveitis - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) ( P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.
ISSN:0022-3476
1097-6833
DOI:10.1016/j.jpeds.2006.04.058